Clinical Drug Investigation

, Volume 31, Issue 2, pp 113–120

Conversion from Epoetin Alfa to Darbepoetin Alfa for Management of Anaemia in a Community Chronic Kidney Disease Centre

A Retrospective Cohort Study
  • Jaya Gobin
  • Aura Cernii
  • Rosella McLean
  • Fredric O. Finkelstein
  • David B. Simon
Original Research Article

Abstract

Background: The management of anaemia in chronic kidney disease (CKD) to achieve current guideline goals is difficult and is hindered by multiple factors, including problems with the scheduling and adjustment of dosing of erythropoiesis-stimulating agents (ESAs) and the frequency of required ESA administration to achieve target haemoglobin (Hgb) levels.

Objective: The primary objective of this study was to examine whether converting a large cohort of CKD patients receiving epoetin alfa to darbepoetin alfa would decrease the frequency of drug administration while permitting an acceptable management of CKD-related anaemia.

Methods: In this retrospective cohort study of practice in a community-based CKD anaemia clinic, we evaluated the effects of conversion of a baseline group of 283 patients from epoetin alfa to darbepoetin alfa with a goal of decreasing the frequency of ESA administration while maintaining Hgb levels within a target range. The study observation period extended for 15 months after the initial conversion. An additional 256 CKD patients were started on darbepoetin alfa during the observation period and the frequency of their injections and the range of their Hgb levels were also monitored.

Results: Following the conversion to darbepoetin alfa, we were able to increase the number of patients on once-monthly injections from 21% to 76% while keeping Hgb levels in the target range and maintaining stable blood pressure control. The mean number of ESA injections/patient/month decreased from 2.1 to 1.3.

Conclusion: In a community-based CKD anaemia clinic, conversion from epoetin alfa to darbepoetin alfa resulted in a decreased frequency of injections needed to maintain Hgb levels within an accepted target range.

References

  1. 1.
    National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47Suppl. 3: S1 1–45Google Scholar
  2. 2.
    McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501–10PubMedCrossRefGoogle Scholar
  3. 3.
    Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53–61PubMedCrossRefGoogle Scholar
  4. 4.
    Pereira BJG. Overcoming barriers to the early detection and treatment of chronic kidney disease and improving outcomes for end-stage renal disease. Am J Manage Care 2002; 8Suppl. 4: S122–35Google Scholar
  5. 5.
    Padhi D, Ni L, Cooke B, et al. An extended terminal half-life for darbepoetin alfa. Clin Pharmacokinet 2006; 45(5): 503–10PubMedCrossRefGoogle Scholar
  6. 6.
    Kampf D, Eckardt KU, Fischer HC, et al. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992; 61(4): 393–8PubMedCrossRefGoogle Scholar
  7. 7.
    Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130(6): 461–70PubMedGoogle Scholar
  8. 8.
    Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005; 64: 113–23PubMedGoogle Scholar
  9. 9.
    McGowan T, Vaccaro NM, Beaver JS, et al. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008; 3: 1006–14PubMedCrossRefGoogle Scholar
  10. 10.
    Spinowitz B, Germain M, Benz R, et al. Randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1015–21PubMedCrossRefGoogle Scholar
  11. 11.
    Germain M, Ram CV, Bhaduri S, et al. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant 2005; 20: 146–52CrossRefGoogle Scholar
  12. 12.
    Padhi D, Ni L, Cooke B, et al. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006; 45(5): 503–10PubMedCrossRefGoogle Scholar
  13. 13.
    Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005; 63(5): 327–34PubMedGoogle Scholar
  14. 14.
    Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–98PubMedCrossRefGoogle Scholar
  15. 15.
    Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071–84PubMedCrossRefGoogle Scholar
  16. 16.
    Pfeffer MA, Burdmann EA, Chen CY, et al., TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019–32PubMedCrossRefGoogle Scholar
  17. 17.
    Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 33–8PubMedCrossRefGoogle Scholar
  18. 18.
    Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2009; 75: 15–23PubMedCrossRefGoogle Scholar
  19. 19.
    Horowitz J, Agarwal A, Huang F, et al. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. J Manag Care Pharm 2009; 15: 741–50PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Jaya Gobin
    • 1
  • Aura Cernii
    • 1
  • Rosella McLean
    • 1
  • Fredric O. Finkelstein
    • 1
  • David B. Simon
    • 1
  1. 1.Hospital of Saint Raphael, Metabolism AssociatesYale UniversityNew HavenUSA
  2. 2.New HavenUSA

Personalised recommendations